EyeGate closes Bayon acquisition, issues 33,798 shares; appoints Eric Daniels as CDO

KIORA PHARMACEUTICALS INC

Acquired Bayon Therapeutics for 33,798 common shares; up to $7.1M in milestone payments possible.
Eric Daniels appointed CDO with base salary AUD$492,000 and option for 50,000 shares.
CEO Brian Strem and new CDO Eric Daniels each owned ~28% of Bayon before acquisition.
Milestone payments tied to clinical trial data and FDA approval of Bayon product candidates.

item 1.01 item 2.01 item 5.02 item 3.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric J. Daniels

Chief Development Officer

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2021-10-21
Filed: October 26, 2021, 7:59 PM ET

the Board of Directors (the “Board”) of the Company appointed Eric J. Daniels, MD, MBA as Chief Development Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric J. Daniels was appointed as Chief Development Officer at KIORA PHARMACEUTICALS INC.

Action: appointed
Role: Chief Development Officer

Exact text from the filing

the Board of Directors (the “Board”) of the Company appointed Eric J. Daniels, MD, MBA as Chief Development Officer of the Company.

View on SEC.gov

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-21-129738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.